16155-03-6

Basic information

• Product Name: 1-METHYL-4-(4-NITROPHENYL)PIPERAZINE
• Synonyms: 1-METHYL-4-(4-NITROPHENYL)PIPERAZINE;1-Methyl-4-(4-nitrophenyl)piperazine95%;1-METHYL-4-(4-NITROPHENYL)PIPERAZINE 95%;Piperazine, 1-Methyl-4-(4-nitrophenyl)-
• CAS NO: 16155-03-6
• Molecular Formula: C₁₁H₁₅N₃O₂
• Molecular Weight: 221.26
• Mol File: 16155-03-6.mol
• Article Data: 92

Chemical Properties

• Melting Point: 109-111°C
• Boiling Point: 369.5 °C at 760 mmHg
• Flash Point: 177.3 °C
• Appearance: /Solid
• Density: 1.198 g/cm³
• Vapor Pressure: 1.18E-05mmHg at 25°C
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 7.41±0.42(Predicted)
• CAS DataBase Reference: 1-METHYL-4-(4-NITROPHENYL)PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-METHYL-4-(4-NITROPHENYL)PIPERAZINE(16155-03-6)
• EPA Substance Registry System: 1-METHYL-4-(4-NITROPHENYL)PIPERAZINE(16155-03-6)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 16155-03-6(Hazardous Substances Data)

Usage

Description

1-Methyl-4-(4-nitrophenyl)piperazine is an organic compound characterized by its red solid appearance. It is a reagent with significant applications in the pharmaceutical industry, particularly in the development of inhibitors for targeted cancer treatments.

Uses

Used in Pharmaceutical Industry:
1-Methyl-4-(4-nitrophenyl)piperazine is used as a reagent for the preparation of diaminopyrimidines, which serve as reversible and irreversible inhibitors of mutant EGFR (epidermal growth factor receptor) tyrosine kinases. These inhibitors are crucial in the treatment of non-small-cell lung cancer, as they help regulate the abnormal cell growth associated with the disease.
Additionally, 1-Methyl-4-(4-nitrophenyl)piperazine is utilized in the preparation of disubstituted pyrimidine compounds. These compounds act as inhibitors for EGFR and/or ALK (anaplastic lymphoma kinase), which are relevant in the treatment of various diseases. By targeting these specific proteins, the compound can potentially improve therapeutic outcomes and provide more effective treatment options for patients.

InChI:InChI=1/C11H15N3O2/c1-12-6-8-13(9-7-12)10-2-4-11(5-3-10)14(15)16/h2-5H,6-9H2,1H3/p+1

Upstream product

• 109-01-3 1-methyl-piperazine 
• 586-78-7 para-nitrophenyl bromide 
• 6269-89-2 1-(4-Nitrophenyl)piperazine 
• 74-88-4 methyl iodide 
• 7440-44-0 pyrographite 
• 100-00-5 4-chlorobenzonitrile 
• 636-98-6 p-nitrobenzene iodide 
• 463-57-0 methanediol 
• 321898-63-9 4-(4-nitrophenyl)piperazine-1-carbaldehyde 
• 50-00-0 formaldehyd 
• 260252-87-7 4-(4'-nitrophenyl)piperazine hydrochloride 
• 350-46-9 4-Fluoronitrobenzene 

Downstream Products

• 16153-81-4 4-(4-Methyl-piperazino)-anilin 
• 125819-00-3 4-(4-methyl-1-piperazinyl)benzenamine dihydrochloride 
• 760975-51-7 1,1-dimethyl-4-(4-nitrophenyl)piperazin-1-ium methyl sulphate 
• 1062073-54-4 6-chloro-2-methoxy-N-(4-(4-methylpiperazin-1-yl)phenyl)acridin-9-amine 
• 1313481-20-7 (6-chloro-1,2,3,4-tetrahydro-acridin-9-yl)-[4-(4-methyl-piperazin-1-yl)-phenyl]-amine 
• 10024-04-1 7-chloro-N-(4-(4-methylpiperazin-1-yl)phenyl)quinolin-4-amine 
• 1393900-88-3 tert-butyl 3-(2-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)ethyl)benzoate 
• 1393900-40-7 3-(2-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)ethyl)benzamide 
• 724455-62-3 4-(4-(4-methylpiperazin-1-yl)phenylamino)-4-oxobutanoic acid 

Relevant articles and documents

Safety-catch linker strategies for the production of radiopharmaceuticals labeled with positron-emitting isotopes

A novel synthetic stratetegy for compounds labeled with the positron-emitting isotope carbon-11 is described. The use of precursors attached to a solid support via safety-catch linkers allows selective release of radiolabeled material, leaving unreacted precursor attached to the support. Two different linkers demonstrate the application to the preparation of radiolabeled N-alkyl tertiary amines and N-alkylsulfonamides. This technique is expected to lead to more widespread use of positron emission tomography for the in vivo analysis of compound behavior. Copyright

Evidence of Rate Limiting Proton Transfer in an SNAr Aminolysis in Acetonitrile under Synthetically Relevant Conditions

An early synthetic step in the synthesis of adavosertib, AZD1775, is the SNAr reaction between 4-fluoronitrobenzene and 1-methylpiperazine in acetonitrile. A simple kinetics-based design of four reaction profiling experiments was used to invest

NOVEL SULFONAMIDE DERIVATIVE WITH FUSED PYRIMIDINE SKELETON, HAVING EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION INHIBITORY EFFECT

The present invention relates to a novel fused pyrimidine based sulfonamide derivative represented by Formula I, a solvate thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition including the same as an active ingredient. The novel fused pyrimidine based sulfonamide derivative of the present invention can effectively suppress the growth of cancer cells and resistance to drugs, which are induced by mutations in the tyrosine kinase domain of epidermal growth factor receptors, or the growth of cancer cells having such resistance.